tiprankstipranks

BioNTech price target raised to $140 from $139 at Morgan Stanley

Morgan Stanley raised the firm’s price target on BioNTech (BNTX) to $140 from $139 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue